Therapeutic angiogenesis to ischemic heart disease by cell transplantation

我们以前已经报道了通过将自体骨髓单个核细胞移植到缺血肢体来治疗血管生成的有效性和安全性(Lancet 2002)。在这项研究中，我们调查了骨髓来源的内皮祖细胞(EPC)移植是否也对缺血性心脏病患者有效。骨髓来源的内皮祖细胞被移植到缺血性心脏病患者的心肌中；他们接受了骨髓来源的CD34细胞移植到左心室不能移植的区域，同时伴随着冠状动脉旁路移植(混合治疗)。在细胞移植前和移植后1个月分别用单光子发射计算机断层扫描(SPECT)检测局部血流量。细胞移植后1个月，内皮祖细胞移植区和移植区血流量均明显增加。未观察到任何副作用。在这项研究中，我们证明了自体骨髓来源的内皮祖细胞移植是一种新的、有前景的临床应用策略，旨在重建缺血心肌的血运。

We have previously reported the effectiveness and safety of therapeutic angiogenesis by transplantation of autologous bone marrow mononuclear cells to ischemic limbs (Lancet 2002). In this study, we investigated whether transplantation of bone marrow-derived endothelial progenitor cells (EPCs) would also be effective in patients with ischemic heart disease. Bone marrow-derived EPCs were transplanted to the myocardium in patients with ischemic heart disease ; They received bone marrow-derived CD34^+ cell transplantation into ungraftable regions of the left ventricle with concomitant coronary artery bypass grafts (hybrid therapy). Before and 1 month after cell transplantation, we assessed the regional blood flow by single photon emission computed tomography (SPECT). The blood flow in the EPC-transplanted region as well as the grafted region was significantly increased at 1 month after cell transplantation. No side effects were observed. In this study, we demonstrated that autologous transplantation of bone marrow-derived EPCs represents a new and promising strategy for clinical application designed to revascularize the ischemic myocardium